Lifecore Biomedical (NASDAQ:LFCR) Announces Earnings Results, Misses Estimates By $0.05 EPS

Lifecore Biomedical (NASDAQ:LFCR) released its earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05), Zacks reports. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The company had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical updated its FY 2025 guidance to EPS.

Lifecore Biomedical Price Performance

NASDAQ:LFCR opened at $5.29 on Friday. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The company has a 50-day moving average of $6.17 and a 200-day moving average of $6.24. Lifecore Biomedical has a 52 week low of $3.68 and a 52 week high of $7.99. The company has a market capitalization of $195.86 million, a price-to-earnings ratio of -9.45 and a beta of 0.96.

Insider Activity at Lifecore Biomedical

In related news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was purchased at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at $3,212,775.58. The trade was a 3.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 32.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Stephens reiterated an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.